Edesa Biotech Inc (EDSA-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low4.16

Day High4.64

Open:4.26

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

November 20, 2023

Edesa Biotech to Present at Dermatology Drug Development Summit

October 26, 2023

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug

October 25, 2023

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

October 12, 2023

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

October 12, 2023

Edesa Biotech Announces One-for-Seven Reverse Share Split

October 10, 2023

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Edesa Biotech to Participate in Swiss Biotech Day

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

February 10, 2023

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

February 1, 2023

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

January 17, 2023

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

December 20, 2022

Edesa Biotech Reports Fiscal Year 2022 Results

December 16, 2022

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

December 2, 2022

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

November 3, 2022

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

September 30, 2022

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

September 8, 2022

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

September 7, 2022

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

August 12, 2022

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Edesa Biotech to Present at ARDS Drug Development Summit

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

Profile

Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.